Inspire Investing LLC Has $392,000 Holdings in Precigen, Inc. $PGEN

Inspire Investing LLC grew its holdings in Precigen, Inc. (NASDAQ:PGEN) by 17.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 275,870 shares of the biotechnology company’s stock after purchasing an additional 40,758 shares during the period. Inspire Investing LLC owned about 0.09% of Precigen worth $392,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. raised its holdings in shares of Precigen by 3.8% in the first quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock valued at $16,801,000 after purchasing an additional 410,595 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new stake in shares of Precigen in the first quarter valued at approximately $4,755,000. Mill Creek Capital Advisors LLC raised its holdings in shares of Precigen by 131.8% in the first quarter. Mill Creek Capital Advisors LLC now owns 255,000 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 145,000 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Precigen in the first quarter valued at approximately $275,000. Finally, Deutsche Bank AG raised its holdings in shares of Precigen by 35.3% in the first quarter. Deutsche Bank AG now owns 91,031 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 23,729 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Wednesday, October 8th. Citigroup restated an “outperform” rating on shares of Precigen in a report on Tuesday, August 19th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. JMP Securities boosted their target price on shares of Precigen from $6.00 to $8.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. upgraded shares of Precigen from an “underweight” rating to a “neutral” rating in a report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Precigen has a consensus rating of “Moderate Buy” and an average price target of $8.25.

Insider Activity at Precigen

In other Precigen news, Director Randal J. Kirk sold 3,596,892 shares of the company’s stock in a transaction on Friday, September 19th. The shares were sold at an average price of $3.68, for a total value of $13,236,562.56. Following the transaction, the director directly owned 8,520,537 shares in the company, valued at $31,355,576.16. The trade was a 29.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nancy H. Agee acquired 15,360 shares of the firm’s stock in a transaction on Tuesday, August 19th. The stock was bought at an average price of $3.20 per share, for a total transaction of $49,152.00. Following the completion of the acquisition, the director owned 192,196 shares of the company’s stock, valued at approximately $615,027.20. The trade was a 8.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 54,221 shares of company stock valued at $214,467 and have sold 6,984,279 shares valued at $25,428,688. Insiders own 47.10% of the company’s stock.

Precigen Price Performance

NASDAQ:PGEN opened at $3.20 on Wednesday. Precigen, Inc. has a one year low of $0.65 and a one year high of $5.22. The company has a market cap of $953.50 million, a P/E ratio of -7.62 and a beta of 1.61. The firm’s fifty day moving average price is $3.49 and its two-hundred day moving average price is $2.19.

Precigen (NASDAQ:PGEN) last released its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.67 million. As a group, equities research analysts expect that Precigen, Inc. will post -0.32 earnings per share for the current year.

Precigen Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.